219 related articles for article (PubMed ID: 36544763)
1. Deciphering a mitochondria-related signature to supervise prognosis and immunotherapy in hepatocellular carcinoma.
Shi Y; Huang G; Jiang F; Zhu J; Xu Q; Fang H; Lan S; Pan Z; Jian H; Li L; Zhang Y
Front Immunol; 2022; 13():1070593. PubMed ID: 36544763
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
Wang Y; Song F; Zhang X; Yang C
Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
[TBL] [Abstract][Full Text] [Related]
3. Identification of a Liver Progenitor Cell-Related Genes Signature Predicting Overall Survival for Hepatocellular Carcinoma.
Li X; Lin J; Pan Y; Cui P; Xia J
Technol Cancer Res Treat; 2021; 20():15330338211041425. PubMed ID: 34866477
[No Abstract] [Full Text] [Related]
4. A novel mitochondrial unfolded protein response-related risk signature to predict prognosis, immunotherapy and sorafenib sensitivity in hepatocellular carcinoma.
Zhang S; Guo H; Wang H; Liu X; Wang M; Liu X; Fan Y; Tan K
Apoptosis; 2024 Jun; 29(5-6):768-784. PubMed ID: 38493408
[TBL] [Abstract][Full Text] [Related]
5. Construction and validation of a novel lysosomal signature for hepatocellular carcinoma prognosis, diagnosis, and therapeutic decision-making.
Chen J; Gao G; He Y; Zhang Y; Wu H; Dai P; Zheng Q; Huang H; Weng J; Zheng Y; Huang Y
Sci Rep; 2023 Dec; 13(1):22624. PubMed ID: 38114725
[TBL] [Abstract][Full Text] [Related]
6. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
[TBL] [Abstract][Full Text] [Related]
7. T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis
Chi H; Zhao S; Yang J; Gao X; Peng G; Zhang J; Xie X; Song G; Xu K; Xia Z; Chen S; Zhao J
Front Immunol; 2023; 14():1137025. PubMed ID: 37006257
[TBL] [Abstract][Full Text] [Related]
8. A necroptosis-related gene signature for predicting prognosis, immune landscape, and drug sensitivity in hepatocellular carcinoma.
Chen J; Wang H; Zhou L; Liu Z; Chen H; Tan X
Cancer Med; 2022 Dec; 11(24):5079-5096. PubMed ID: 35560794
[TBL] [Abstract][Full Text] [Related]
9. Five metastasis-related mRNAs signature predicting the survival of patients with liver hepatocellular carcinoma.
Chen C; Liu YQ; Qiu SX; Li Y; Yu NJ; Liu K; Zhong LM
BMC Cancer; 2021 Jun; 21(1):693. PubMed ID: 34116652
[TBL] [Abstract][Full Text] [Related]
10. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.
Chen J; Chen X; Li T; Wang L; Lin G
Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273
[TBL] [Abstract][Full Text] [Related]
11. Signature construction and molecular subtype identification based on immune-related genes for better prediction of prognosis in hepatocellular carcinoma.
Sun L; Wu Z; Dong C; Yu S; Huang H; Chen Z; Wu Z; Yin X
BMC Med Genomics; 2023 Jun; 16(1):130. PubMed ID: 37316840
[TBL] [Abstract][Full Text] [Related]
12. Disulfidptosis-related signatures for prognostic and immunotherapy reactivity evaluation in hepatocellular carcinoma.
Zhao J; Luo Z; Fu R; Zhou J; Chen S; Wang J; Chen D; Xie X
Eur J Med Res; 2023 Dec; 28(1):571. PubMed ID: 38057871
[TBL] [Abstract][Full Text] [Related]
13. Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis.
Yan Z; He M; He L; Wei L; Zhang Y
Front Immunol; 2021; 12():723271. PubMed ID: 34925311
[TBL] [Abstract][Full Text] [Related]
14. A novel epithelial-mesenchymal transition gene signature for the immune status and prognosis of hepatocellular carcinoma.
Shi Y; Wang J; Huang G; Zhu J; Jian H; Xia G; Wei Q; Li Y; Yu H
Hepatol Int; 2022 Aug; 16(4):906-917. PubMed ID: 35699863
[TBL] [Abstract][Full Text] [Related]
15. A novel natural killer-related signature to effectively predict prognosis in hepatocellular carcinoma.
Xi D; Wang J; Yang Y; Ji F; Li C; Yan X
BMC Med Genomics; 2023 Sep; 16(1):211. PubMed ID: 37674210
[TBL] [Abstract][Full Text] [Related]
16. Identification of Ferroptosis-related molecular model and immune subtypes of hepatocellular carcinoma for individual therapy.
Long S; Chen Y; Wang Y; Yao Y; Xiao S; Fu K
Cancer Med; 2023 Jan; 12(2):2134-2147. PubMed ID: 35841206
[TBL] [Abstract][Full Text] [Related]
17. Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma.
Zhang X; Zhuge J; Liu J; Xia Z; Wang H; Gao Q; Jiang H; Qu Y; Fan L; Ma J; Tan C; Luo W; Luo Y
Front Immunol; 2023; 14():1153423. PubMed ID: 37006285
[TBL] [Abstract][Full Text] [Related]
18. Mining prognostic markers of Asian hepatocellular carcinoma patients based on the apoptosis-related genes.
Yan J; Cao J; Chen Z
BMC Cancer; 2021 Feb; 21(1):175. PubMed ID: 33602168
[TBL] [Abstract][Full Text] [Related]
19. A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma.
Zhang G; Zhang K; Zhao Y; Yang Q; Lv X
BMC Cancer; 2022 Oct; 22(1):1103. PubMed ID: 36307751
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
